Bajaj Healthcare soars after signing deal for supply of 15 APIs with UK/EU customers
Mumbai, Feb. 28 -- Under this agreement, the company will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent.
The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat.
Anil Jain, joint managing director, Bajaj Healthcare said: "I am thrilled to share this strategic collaboration which underscores Bajaj Healthcare Ltd.'s commitment to innovation, excellence, and meeting the evolving needs of the pharmaceutical industry.
By harnessing our expertise and state-of-the-art infrastructure, we are poised to...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.